Elevation Oncology, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Elevation Oncology, Inc. Director Alan B. Sandler reported the disposition of stock options as the company completed its merger with Concentra Biosciences, LLC, involving a tender offer of $0.36 cash per share plus a contingent value right.
Elevation Oncology Director Darcy Mootz disposed of all stock options as part of the company's merger with Concentra Biosciences, receiving cash and contingent value rights.
Elevation Oncology director Steve Elms disposed of all stock options on July 23, 2025, as part of the company's merger with Concentra Biosciences, receiving cash and contingent value rights for eligible options.
Form 4: Elevation Oncology Director Disposes Shares and Options Following Concentra Biosciences Merger
Elevation Oncology Director Timothy P. Clackson disposed of all common stock and converted stock options as part of the company's acquisition by Concentra Biosciences for $0.36 per share plus a contingent value right.
Elevation Oncology, Inc. Director Julie M. Cherrington disposed of all her stock options as part of the company's acquisition by Concentra Biosciences, LLC.
Elevation Oncology director R. Michael Carruthers disposed of stock options as part of the company's acquisition by Concentra Biosciences, with most options cancelled for no consideration due to exercise prices exceeding the cash offer.
Elevation Oncology's Chief Financial Officer, Tammy Furlong, disposed of common stock and had stock options cancelled as part of the company's merger with Concentra Biosciences.
Elevation Oncology, Inc. CEO Joseph J. Ferra Jr. reported the vesting of restricted stock units and a subsequent sale of shares for tax purposes, increasing his direct beneficial ownership.
Elevation Oncology, Inc. Director Alan B. Sandler was granted 35,000 stock options with an exercise price of $0.3051, vesting fully on the one-year anniversary of the grant date.
Darcy Mootz, a Director at Elevation Oncology, Inc. (ELEV), was granted 35,000 stock options with an exercise price of $0.3051 per share, vesting over one year.
Elevation Oncology, Inc. director Steve Elms was granted 35,000 stock options with an exercise price of $0.3051, vesting over one year, though the pecuniary interest belongs to Aisling Capital.
Elevation Oncology, Inc. Director Timothy P. Clackson was granted 35,000 stock options with an exercise price of $0.3051, vesting on the one-year anniversary of the grant date.
Elevation Oncology, Inc. director Julie M Cherrington was granted 35,000 stock options with an exercise price of $0.3051, vesting over one year.
Elevation Oncology, Inc. director R Michael Carruthers was granted 35,000 stock options with an exercise price of $0.3051, vesting fully in one year.
Tammy Furlong, CFO of Elevation Oncology, reports the vesting and disposal of restricted stock units and common stock transactions.
CEO Joseph Ferra Jr. of Elevation Oncology reports the acquisition and disposal of common stock and restricted stock units.
CEO Joseph J. Ferra Jr. of Elevation Oncology, Inc. reports transactions involving common stock and restricted stock units.
Valerie Jansen, Chief Medical Officer of Elevation Oncology, reports the vesting of restricted stock units and associated tax withholding, along with the grant of stock options.
Tammy Furlong, CFO of Elevation Oncology, reports the acquisition and disposal of common stock and derivative securities, including stock options and restricted stock units, on February 15, 2025.
David Dornan, Chief Scientific Officer of Elevation Oncology, exercised stock options and sold shares to cover tax obligations on February 15, 2025.
CEO Joseph J. Ferra Jr. exercised stock options and sold shares of Elevation Oncology, Inc. on February 15, 2025.
Elevation Oncology's CEO, Joseph J. Ferra Jr., reports the acquisition and disposal of common stock and restricted stock units on December 16, 2024.
Elevation Oncology's Chief Financial Officer, Tammy Furlong, reported the acquisition of 300 shares and the disposal of 98 shares of common stock on November 15, 2024.
CEO Joseph Ferra Jr. reports stock transactions involving common stock and restricted stock units.
Tammy Furlong, CFO of Elevation Oncology, reports the vesting of restricted stock units and associated tax withholding.
CEO Joseph Ferra Jr. reports the vesting of restricted stock units and subsequent tax withholding of shares.
Director Alan B. Sandler acquired 35,000 stock options in Elevation Oncology, Inc. on June 13, 2024.
Darcy Mootz, a director at Elevation Oncology, acquired 35,000 stock options on June 13, 2024, exercisable at $3.35.
Director Steven Elms of Elevation Oncology, Inc. (ELEV) was granted stock options for 35,000 shares on June 13, 2024, vesting one year from the grant date.
Timothy P. Clackson, a director of Elevation Oncology, Inc., acquired stock options for 35,000 shares on June 13, 2024.